Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Srinivas Govindan"'
Autor:
Ravi Yadav, Srinivas Govindan, Courtney Daczkowski, Andrew Mesecar, Srinivas Chakravarthy, Nicholas Noinaj
Publikováno v:
eLife, Vol 10 (2021)
Lactoferrin-binding protein B (LbpB) is a lipoprotein present on the surface of Neisseria that has been postulated to serve dual functions during pathogenesis in both iron acquisition from lactoferrin (Lf), and in providing protection against the cat
Externí odkaz:
https://doaj.org/article/0388a112fc7f44eaa9ea04966a3de0cb
Autor:
Krithika Arrabothu, Srinivas Govindan, Wilson Rodriguez, Sophie Xie, Christopher Tapia, Robert White
Publikováno v:
Monday, April 24.
Autor:
Brittany E. Wichman, Jamie Nilson, Srinivas Govindan, Alan Chen, Aditya Jain, Varsha Arun, Juana Derdoy, Joseph Krebs, Ajay K. Jain
Publikováno v:
Nutr Clin Pract
Parenteral Nutrition (PN) is a therapy that delivers essential nutrients intravenously to patients that are unable to meet their nutritional requirements via standard enteral feeding. This methodology is often referred to as Parenteral Nutrition (PN)
Publikováno v:
Journal of Clinical Oncology. 41:75-75
75 Background: The two common therapies for metastatic castrate resistant prostate cancer (mCRPC), enzalutamide (ENZ) and abiraterone (AA), have different effectiveness in patients with diabetes mellitus and obesity due to different mechanisms of act
Autor:
Srinivas Chakravarthy, Srinivas Govindan, Andrew D. Mesecar, Ravi Yadav, Nicholas Noinaj, Courtney M. Daczkowski
Publikováno v:
eLife
eLife, Vol 10 (2021)
eLife, Vol 10 (2021)
Lactoferrin-binding protein B (LbpB) is a lipoprotein present on the surface of Neisseria that has been postulated to serve dual functions during pathogenesis in both iron acquisition from lactoferrin (Lf), and in providing protection against the cat
Publikováno v:
Journal of Clinical Oncology. 40:113-113
113 Background: In metastatic castrate resistant prostate cancer (mCRPC) there is a lack of studies that explore the interaction of comorbidities on treatment outcomes, which presents a challenge in choosing the right drug. In patients with diabetes
Autor:
Forest Riekhof, Suhong Luo, Nina Cheranda, Srinivas Govindan, Kristen Marie Sanfilippo, Martin W. Schoen
Publikováno v:
Journal of Clinical Oncology. 40:92-92
92 Background: Abiraterone (AA) and Enzalutamide (ENZ) are both hormone therapies used in the treatment of metastatic castrate resistant prostate cancer (mCRPC). Due to a lack of large comparative studies, they are currently used interchangeably, but
Autor:
Nina Cheranda, Suhong Luo, Forest Riekhof, Srinivas Govindan, Kristen Marie Sanfilippo, Martin W. Schoen
Publikováno v:
Journal of Clinical Oncology. 40:116-116
116 Background: In metastatic castrate resistant prostate cancer (mCRPC), the oral treatments of enzalutamide (ENZ) and abiraterone (AA) are used interchangeably because there are few large-scale comparative studies of the therapies. However, both dr
Autor:
Srinivas Chakravarthy, Srinivas Govindan, Andrew D. Mesecar, Courtney M. Daczkowski, Nicholas Noinaj, Ravi Yadav
Publikováno v:
Acta Crystallographica Section A Foundations and Advances. 77:a181-a181